Jump to navigation Jump to search
CD70 molecule
Alt. symbolsCD27LG, TNFSF7
Other data
LocusChr. 19 p13

CD70 (Cluster of Differentiation 70) is a ligand for CD27.

Clinical significance

The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.[1]

Drug development

ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.[2]

Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.[3]

See also


  1. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005). "Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas". Mol. Cancer Ther. 4 (12): 2037–44. doi:10.1158/1535-7163.MCT-05-0253. PMID 16373719.
  2. "ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action". arGEN-X. Retrieved 28 February 2015.
  3. Seattle Genetics Third Quarter 2013 Financial Report

External links